About Trevena, inc
Trevena, Inc. is a biopharmaceutical company that has been dedicated to the development and commercialization of novel medicines for patients with Central Nervous System (CNS) conditions since its inception. The company's mission is to improve the lives of patients suffering from CNS disorders by providing innovative treatments that address unmet medical needs.
Trevena, Inc. was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania. The company's research and development efforts are focused on discovering new therapies for pain management, acute heart failure, and other CNS disorders.
The company's lead product candidate is OLINVO® (oliceridine injection), which has been approved by the U.S. Food and Drug Administration (FDA) for the management of moderate-to-severe acute pain in adults who require an intravenous opioid analgesic for an extended period of time.
OLINVO® represents a significant advancement in pain management because it provides rapid relief without many of the side effects associated with traditional opioids such as respiratory depression or sedation. This makes it an ideal option for patients who require long-term treatment for chronic pain conditions.
In addition to OLINVO®, Trevena, Inc.'s pipeline includes several other promising drug candidates that are currently undergoing clinical trials. These include TRV250, a G protein biased ligand targeting delta-opioid receptors; TRV734, a novel oral mu-opioid receptor agonist; and TRV0456/TRV0274, which target adenosine A1 receptors to treat acute heart failure.
Trevena's commitment to innovation extends beyond its drug development efforts as well. The company has also developed proprietary technology platforms that enable more efficient drug discovery processes through advanced computational modeling techniques.
One such platform is Adynxx™️ technology which uses machine learning algorithms to identify potential targets within the nervous system that could be used to develop new treatments for chronic pain conditions like osteoarthritis or neuropathic pain syndromes.
Another platform developed by Trevena is called Biased Ligand Technology™️ which allows researchers to design drugs with specific pharmacological properties based on their intended therapeutic use case rather than relying solely on trial-and-error methods during preclinical testing phases.
Overall Trevena Inc.'s dedication towards developing innovative solutions towards treating CNS disorders makes them one of the leading biopharmaceutical companies globally today!